RIGL vs. IAS
RIGL (Rigel Pharmaceuticals, Inc.) and IAS (Integral Ad Science Holding Corp.) are both stocks. RIGL operates in Biotechnology (Healthcare), while IAS operates in Advertising Agencies (Communication Services). Their 0.23 correlation means their historical movements had little consistent relationship.
Performance
RIGL vs. IAS - Performance Comparison
Loading charts...
Returns By Period
RIGL
- 1D
- -3.28%
- 1M
- -4.93%
- 6M
- 5.59%
- YTD
- -14.06%
- 1Y
- 68.01%
- 3Y*
- 40.40%
- 5Y*
- -1.65%
- 10Y*
- 3.86%
- ALL TIME*
- -10.60%
IAS
- 1D
- —
- 1M
- —
- 6M
- —
- YTD
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- —
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $11.43M | $14.01M | $13.32M |
RIGL vs. IAS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
RIGL Rigel Pharmaceuticals, Inc. | -14.06% | 154.64% | 16.00% | -3.33% | -43.40% | -40.45% |
IAS Integral Ad Science Holding Corp. | 0.00% | -0.96% | -27.45% | 63.71% | -60.42% | 0.95% |
Correlation
The correlation between RIGL and IAS is 0.05, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.05 |
Correlation (3Y) Balances recent behavior with more history. | 0.21 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.23 |
Correlation (All Time) Calculated using the full available price history since Jun 30, 2021 | 0.23 |
The correlation between RIGL and IAS shifts across timeframes, from 0.05 (1 year) to 0.23 (all time), reflecting how their relationship changes across market environments.
Fundamentals
RIGL:
$681.06M
IAS:
$1.74B
RIGL:
$18.94
IAS:
$0.28
RIGL:
1.94
IAS:
37.58
RIGL:
0.00
IAS:
0.22
RIGL:
2.36
IAS:
2.97
RIGL:
1.81
IAS:
1.59
RIGL:
$299.77M
IAS:
$590.67M
RIGL:
$279.95M
IAS:
$457.31M
RIGL:
$125.80M
IAS:
$119.85M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RIGL vs. IAS — Risk / Return Rank
RIGL
IAS
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
RIGL vs. IAS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Rigel Pharmaceuticals, Inc. (RIGL) and Integral Ad Science Holding Corp. (IAS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RIGL | IAS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | 1.25 | — | — |
| Calmar ratioReturn relative to maximum drawdown | 1.50 | — | — |
| Martin ratioReturn relative to average drawdown | 2.51 | — | — |
Loading charts...
Drawdowns
RIGL vs. IAS - Drawdown Comparison
Loading charts...
Drawdown Indicators
| RIGL | IAS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.37% | — | — |
Max Drawdown (1Y)Largest decline over 1 year | -50.08% | — | — |
Max Drawdown (3Y)Largest decline over 3 years | -50.76% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -83.85% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -86.40% | — | — |
Current DrawdownCurrent decline from peak | -96.55% | — | — |
Average DrawdownAverage peak-to-trough decline | -90.93% | — | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 29.86% | — | — |
Volatility
RIGL vs. IAS - Volatility Comparison
Loading charts...
Volatility by Period
| RIGL | IAS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.97% | — | — |
Volatility (6M)Calculated over the trailing 6-month period | 34.77% | — | — |
Volatility (1Y)Calculated over the trailing 1-year period | 70.02% | — | — |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 85.52% | — | — |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 82.76% | — | — |
Dividends
RIGL vs. IAS - Dividend Comparison
Neither RIGL nor IAS has paid dividends to shareholders.
Financials
RIGL vs. IAS - Financials Comparison
This section allows you to compare key financial metrics between Rigel Pharmaceuticals, Inc. and Integral Ad Science Holding Corp.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RIGL vs. IAS - Profitability Comparison
RIGL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Rigel Pharmaceuticals, Inc. reported a gross profit of 54.21M and revenue of 58.82M. Therefore, the gross margin over that period was 92.2%.
IAS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Integral Ad Science Holding Corp. reported a gross profit of 118.81M and revenue of 154.36M. Therefore, the gross margin over that period was 77.0%.
RIGL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Rigel Pharmaceuticals, Inc. reported an operating income of 11.89M and revenue of 58.82M, resulting in an operating margin of 20.2%.
IAS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Integral Ad Science Holding Corp. reported an operating income of 7.57M and revenue of 154.36M, resulting in an operating margin of 4.9%.
RIGL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Rigel Pharmaceuticals, Inc. reported a net income of 8.65M and revenue of 58.82M, resulting in a net margin of 14.7%.
IAS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Integral Ad Science Holding Corp. reported a net income of 7.05M and revenue of 154.36M, resulting in a net margin of 4.6%.
Frequently Asked Questions
RIGL and IAS have a correlation of 0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for RIGL and IAS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer